Biotech Values

[DewDiligence]

…traditional chemo does not show this subgroup pfs harm to anywhere near the degree it often pops up in the more targetted kinase actors. But again, I'd need to do more research to make it less anecdotal.

I think you’re on the right track. Moreover, I don’t find it counter-intuitive that a targeted drug could accelerate tumor growth (thereby shortening PFS) in certain patients who are especially susceptible to alternative growth pathways triggered by the targeted drug being administered.